Fig. 9

Analysis of therapeutic sensitivity. (A) Axitinib. (B) Ibrutinib. (C) Osimertinib. (D) Ruxolitinib. (E) Crizotinib. (F) Lapatinib. (G) Linsitinib. (H) Nilotinib